je.st
news
Tag: clinical
RadCore Labs Moves Clinical Research Images To INFINITT Cloud
2013-04-01 04:00:24| dairynetwork News Articles
INFINITT North America, a leading provider of image and information management technologies for healthcare, announced recently that they signed an agreement to provide cloud-based image archiving, retrieval and viewing capabilities to California-based RadCore Labs LLC.
Tags: research
images
clinical
moves
Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
2013-03-28 09:57:29| dairynetwork Home Page
Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.
Biodel Completes Enrollment In Phase 2 Clinical Trial Of Ultra-Rapid-Acting Insulin Candidate BIOD-123 For The Treatment Of Diabetes
2013-03-28 09:57:29| dairynetwork News Articles
Biodel Inc. (Nasdaq:BIOD) today announced the completion of patient enrollment in a Phase 2 clinical study of ultra-rapid-acting prandial insulin candidate BIOD-123 for the treatment of diabetes. The trial will evaluate the use of BIOD-123 versus Humalog® on measures of HbA1c, postprandial glucose excursions, glycemic variability, hypoglycemic event rates and weight changes.
Clinical Device Assesment Service Brochure
2013-03-28 01:59:00| dairynetwork Downloads
As U.S. hospitals move through the phases of the EMR Adoption Model, the ability to capture and manage patient data from intelligent medical devices will quickly become a necessity in order to advance patient safety and better clinicaloutcomes.
Tags: service
device
clinical
brochure
Merck and Luminex Corporation Enter Agreement to Develop Companion Diagnostic to Support Investigational BACE inhibitor Clinical Development Program for Alzheimers Disease
2013-03-13 13:30:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. & AUSTIN, Texas Collaboration to Support Patient Selection for the Clinical Development of MK-8931, Mercks Lead Investigational Medicine for Alzheimers Disease WHITEHOUSE STATION, N.J. & AUSTIN, Texas--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Luminex Corporation (NASDAQ:LMNX) have signed a collaboration and license agreement to develop a companion diagnostic device that will be evaluated to help screen patients for recruitment into Merck's clinical development program for MK-8931, a novel oral beta amyloid precursor protein site cleaving enzyme (BACE) inhibitor and Merck's lead investigational candidate for Alzheimer's disease (AD). Language: English Contact HTML: Media Contacts:MerckCaroline Lappetito, 267-305-7639orLuminexMimi Torrington, 512-219-8020mtorrington@luminexcorp.comorInvestor Contacts:MerckCarol Ferguson, 908-423-4465orLuminexMatt Scalo, 512-336-3587mscalo@luminexcorp.com Ticker Slug: Ticker: MRK Exchange: NYSE Ticker: LMNX Exchange: NASDAQ read more
Tags: support
enter
development
program
Sites : [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] next »